Universitätsklinikum Würzburg

Hematological immune related adverse events after treatment with immune checkpoint inhibitors (2021) Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, et al. Journal article Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021) Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, et al. Journal article, Review article Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma (2021) Leich E, Schreder M, Pischimarov J, Stuhmer T, Steinbrunn T, Rudelius M, Bruennert D, et al. Journal article Diagnostic performance of (1→3)-β-d-glucan alone and in combination with aspergillus pcr and galactomannan in serum of pediatric patients after allogeneic hematopoietic stem cell transplantation (2021) Springer J, Held J, Mengoli C, Schlegel PG, Gamon F, Traeger J, Kurzai O, et al. Journal article Differential responses to bioink‐induced oxidative stress in endothelial cells and fibroblasts (2021) Genc H, Hazur J, Karakaya E, Dietel B, Bider F, Groll J, Alexiou C, et al. Journal article Robustness of convolutional neural networks in recognition of pigmented skin lesions (2021) Maron RC, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hauschild A, et al. Journal article Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future (2021) Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, Sonneveld P, et al. Journal article Idecabtagene vicleucel in relapsed and refractory multiple myeloma (2021) Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, et al. Journal article Evaluation of plaque characteristics and inflammation using magnetic resonance imaging (2021) Andelovic K, Winter P, Jakob PM, Bauer WR, Herold V, Zernecke A Journal article Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study (2021) Wockel A, Brucker C, Decker T, Falbrede J, Forstbauer H, Gohler T, Hoffmann O, et al. Conference contribution